Stock PMN PROMIS NEUROSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

ProMIS Neurosciences, Inc. Stock

Equities

PMN

CA74346M4065

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
1.96 USD -1.26% Intraday chart for ProMIS Neurosciences, Inc. -1.01% +70.43%
Apr. 30 ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies CI
Apr. 09 ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 50.85M 37.13M
Net income 2024 * -38M -27.75M Net income 2025 * -46M -33.59M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.78 x
P/E ratio 2025 *
-1.8 x
Employees 7
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.65%
More Fundamentals * Assessed data

Chart ProMIS Neurosciences, Inc.

Dynamic Chart

Latest news about ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies CI
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ProMIS Neurosciences, Inc. Announces Management Changes CI
ProMIS Neurosciences, Inc. Announces CEO Changes CI
ProMIS Neurosciences Announces Publication on Novel Target for ALS CI
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BTIG Starts ProMIS Neurosciences With Buy Rating, Price Target is $8 MT
ProMIS Neurosciences Files Mixed Shelf MT
ProMIS Neurosciences, Inc. announced that it has received $20.483758 million in funding from Affinity Asset Advisors, LLC, Ally Bridge Group, Sphera Healthcare US Inc. CI
ProMIS Neurosciences Up 48% After Hours as it Raises C$20.4 In a Private Placement of Share Units MT
ProMIS Neurosciences, Inc. announced that it expects to receive funding from Affinity Asset Advisors, LLC, Ally Bridge Group, Sphera Healthcare US Inc. and others CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news

Analyst Recommendations on ProMIS Neurosciences, Inc.

BTIG Starts ProMIS Neurosciences With Buy Rating, Price Target is $8 MT
More recommendations

Press releases ProMIS Neurosciences, Inc.

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies AQ
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS AQ
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April AQ
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April  AQ
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights AQ
More press releases

Quotes and Performance

1 day-1.26%
1 week-1.01%
Current month-2.15%
1 month-4.13%
3 months-5.31%
6 months+10.11%
Current year+70.43%
More quotes

Highs and lows

1 week
1.40
Extreme 1.4
2.10
1 month
1.40
Extreme 1.4
2.61
Current year
1.17
Extreme 1.1659
3.10
1 year
0.95
Extreme 0.95
8.95
3 years
0.95
Extreme 0.95
13.80
5 years
0.95
Extreme 0.95
13.82
10 years
0.95
Extreme 0.95
42.00
More quotes

Managers and Directors - ProMIS Neurosciences, Inc.

Managers TitleAgeSince
Neil Warma CEO
 Chief Executive Officer 61 21-05-12
Neil Cashman FOU
 Founder 72 04-01-22
Eugene Williams CHM
 Chairman 64 15-06-28
Members of the board TitleAgeSince
William W. Wyman BRD
 Director/Board Member 86 14-03-07
Neil Cashman FOU
 Founder 72 04-01-22
Neil Warma CEO
 Chief Executive Officer 61 21-05-12
More insiders

Quotes

Date Price Change Volume
24-05-03 1.96 -1.26% 2,280
24-05-02 1.985 +3.45% 4,583
24-05-01 1.919 -4.21% 21,416
24-04-30 2.003 +0.16% 8,902
24-04-29 2 +1.01% 14,057

Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT

More quotes

Company Profile

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
Sector
Biotechnology & Medical Research
Calendar
2024-05-13 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.682 CAD
Average target price
12.02 CAD
Spread / Average Target
+348.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PROMIS NEUROSCIENCES, INC. Stock ProMIS Neurosciences, Inc.
+70.43% 37.16M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PMN Stock